[BCM] [ALPS] [E3] [BIA] [P2] [CBF] [2] Pharmaceutical Procurement and Supply Management

CBF-2 Pharmaceutical Procurement and Supply Management

The purpose of evaluating business impacts during a Business Impact Analysis (BIA) is to determine the consequences of disrupting each Sub-Critical Business Function that supports Pharmaceutical Procurement and Supply Management.

While all business functions contribute to the overall delivery of pharmaceutical procurement services, they do not carry the same level of operational criticality or consequence if interrupted. Understanding these differences enables ALPS Healthcare to establish evidence-based recovery priorities and allocate continuity resources where they are needed most.

Business impacts should be analysed across multiple dimensions because a disruption rarely affects only one aspect of the organisation.

Depending on the affected Sub-Critical Business Function, the primary consequence may involve operational delays, regulatory non-compliance, financial losses, supplier failures, technology outages, reputational damage, or reduced healthcare service delivery.

Evaluating each impact area independently provides a comprehensive understanding of organisational risk and supports proportionate recovery strategies.

The assessment of financial impacts, affected Business Unit Minimum Business Continuity Objectives (BU MBCOs), and operational consequences provides the foundation for determining Recovery Time Objectives (RTOs), identifying critical resource requirements, developing Business Continuity Strategies, and preparing Business Continuity Plans (BCPs).

For ALPS Healthcare, these assessments ensure that continuity measures are aligned with the critical need to maintain a secure, compliant, and uninterrupted supply of pharmaceuticals to Singapore's public healthcare institutions.

Table P2: Impact Area Assessment for CBF-2

Sub-CBF Code	Sub-Critical Business Function	Impact Area	Financial Impact – Monetary Loss (Estimated)	Financial Impact – Calculation Formula	Impact on BU MBCO – Affected MBCO	Impact on BU MBCO – Business Impact	Remarks / Description
CBF-2.1	Pharmaceutical Demand Forecasting	Operational	SGD 150,000	Emergency procurement cost + inventory imbalance cost	Daily forecasting of essential medicines	Unable to accurately forecast demand, increasing stock-out or overstock risk.	Critical medicines may become unavailable or excessive inventory may expire.
CBF-2.2	Pharmaceutical Requirements Planning	Operational	SGD 200,000	Additional procurement cost + urgent replenishment cost	Priority procurement planning	Essential medicine procurement plans cannot be completed within required timeframes.	Procurement priorities become misaligned with healthcare demand.
CBF-2.3	Approved Drug Catalogue Management	Regulatory	SGD 80,000	Product correction cost + administrative recovery cost	Access to current approved drug catalogue	Procurement may use outdated or unauthorised pharmaceutical information.	Increased regulatory and patient safety risks.
CBF-2.4	Supplier Qualification and Evaluation	Third-Party Dependency	SGD 300,000	Supplier replacement cost + procurement delay cost	Qualification of suppliers for essential medicines	New suppliers cannot be approved to support continuity of medicine supply.	Reduced supplier resilience and increased dependency on existing vendors.
CBF-2.5	Pharmaceutical Tender and Sourcing Management	Operational	SGD 500,000	Delayed sourcing cost + emergency purchasing premium	Procurement of shortage-critical medicines	Critical tenders cannot be completed, delaying medicine availability.	Significant procurement delays and higher acquisition costs.
CBF-2.6	Contract and Pricing Management	Financial	SGD 250,000	Contract variation cost + increased purchase price	Maintenance of active pharmaceutical contracts	Emergency purchasing may proceed without favourable contract pricing.	Procurement expenditure increases substantially during disruption.
CBF-2.7	Purchase Order Processing	Operational	SGD 450,000	Delayed order value + manual processing cost	Timely processing of priority purchase orders	Essential medicine orders cannot be issued within emergency timelines.	Suppliers experience ordering delays affecting healthcare institutions.
CBF-2.8	Regulatory and Product Compliance Verification	Regulatory	SGD 600,000	Compliance remediation cost + potential regulatory penalties	Regulatory verification before procurement	Medicines cannot be released for procurement without compliance verification.	Regulatory breaches and patient safety concerns may arise.
CBF-2.9	Pharmaceutical Supply Scheduling	Third-Party Dependency	SGD 350,000	Delivery delay cost + expedited logistics cost	Daily coordination of medicine deliveries	Essential deliveries become delayed or rescheduled.	Hospitals may experience interruptions to pharmaceutical replenishment.
CBF-2.10	Pharmaceutical Receipt and Inspection Coordination	Operational	SGD 220,000	Receiving delay cost + inspection overtime	Same-day receipt and verification	Incoming medicines cannot be released promptly into inventory.	Distribution delays increase across healthcare facilities.
CBF-2.11	Cold Chain and Controlled Storage Coordination	Operational	SGD 1,200,000	Value of temperature-sensitive inventory lost + replacement cost	Continuous compliant cold-chain storage	Cold-chain integrity cannot be maintained for critical pharmaceuticals.	High-value vaccines and biologics may become unusable.
CBF-2.12	Pharmaceutical Inventory Replenishment	Operational	SGD 750,000	Emergency replenishment cost + stock-out recovery cost	Emergency safety stock maintenance	Safety stock levels cannot be sustained for essential medicines.	Increased risk of medicine shortages across hospitals.
CBF-2.13	Drug Shortage Monitoring and Mitigation	Operational	SGD 900,000	Alternative sourcing cost + shortage mitigation cost	Alternative sourcing for critical medicines	Medicine shortages cannot be identified or mitigated promptly.	Extended shortages directly affect patient treatment capability.
CBF-2.14	Supplier Performance Management	Third-Party Dependency	SGD 180,000	Supplier remediation cost + procurement administration cost	Monitoring of critical supplier performance	Supplier performance deterioration remains undetected.	Increased delivery failures and reduced supply reliability.
CBF-2.15	Pharmaceutical Recall Coordination	Regulatory	SGD 1,500,000	Recall execution cost + product replacement cost + communication cost	Immediate recall and product isolation capability	Unsafe medicines cannot be rapidly identified and withdrawn.	Serious patient safety, regulatory, and reputational consequences.
CBF-2.16	Procurement Risk Monitoring	Operational	SGD 250,000	Risk response cost + disruption management cost	Daily monitoring of procurement risks	Emerging procurement threats remain unidentified until disruption occurs.	Reduced preparedness for supply chain disruptions.
CBF-2.17	Pharmaceutical Procurement Information Management	Information	SGD 180,000	Data recovery cost + manual reconstruction effort	Access to procurement records and contracts	Procurement documentation becomes unavailable for operational decisions.	Reduced auditability and slower emergency procurement decisions.
CBF-2.18	Pharmaceutical Procurement Reporting and Governance	Reputation	SGD 120,000	Reporting recovery cost + management coordination cost	Daily reporting on procurement status	Management loses visibility of procurement performance during incidents.	Decision-making becomes slower due to reduced situational awareness.

The assessment of business impacts for each Sub-Critical Business Function provides ALPS Healthcare with a structured understanding of the operational, financial, regulatory, technological, and third-party consequences associated with disruptions to Pharmaceutical Procurement and Supply Management.

By analysing each business function independently, the Business Impact Analysis identifies where interruptions would have the greatest effect on medicine availability, healthcare service continuity, regulatory compliance, and organisational performance.

Estimating the financial impact of disruptions enables management to quantify the potential cost of downtime, evaluate the economic benefits of continuity investments, and prioritise mitigation measures based on risk exposure.

Although the financial values presented are indicative for Business Impact Analysis purposes, they provide a practical basis for comparing recovery options, justifying resilience initiatives, and supporting informed investment decisions.

The impact analysis also establishes the relationship between each Sub-Critical Business Function and its corresponding Business Unit Minimum Business Continuity Objective (BU MBCO).

This linkage enables ALPS Healthcare to determine appropriate Recovery Time Objectives (RTOs), prioritise recovery sequencing, identify critical resource dependencies, and develop targeted Business Continuity Strategies and Business Continuity Plans (BCPs).

Collectively, these outputs strengthen organisational resilience by ensuring that essential pharmaceutical procurement capabilities can be maintained and restored in a structured, risk-informed, and timely manner during disruptive events.

eBook 3: Starting Your BCM Implementation
MBCO [x]	P&S [x]	RAR T1 [x]	RAR T2 [x]	RAR T3 [x]	BCS T1 [x]	CBF

CBF-2 Pharmaceutical Procurement and Supply Management
DP	BIAQ P1	BIAQ P2	BIAQ P3	BIAQ P4	BIAQ P5	BIAQ P6

		BCS T2	BCS T3	PD

More Information About Business Continuity Management Courses

To learn more about the course and schedule, click the buttons below for the BCM-300 Business Continuity Management Implementer [BCM-3] and the BCM-5000 Business Continuity Management Expert Implementer [BCM-5].



	Please feel free to send us a note if you have any questions.

Implementing Business Continuity Management for ALPS Healthcare: An Enterprise Implementation Guide

[BCM] [ALPS] [E3] [BIA] [P2] [CBF] [2] Pharmaceutical Procurement and Supply Management

Business Continuity Management Certified Planner-Specialist-Expert

CBF-2 Pharmaceutical Procurement and Supply Management

More Information About Business Continuity Management Courses

Your Comments Here:

More Posts

Implementing Business Continuity Management for ALPS Healthcare: An Enterprise Implementation Guide

[BCM] [ALPS] [E3] [BIA] [P2] [CBF] [2] Pharmaceutical Procurement and Supply Management

hbspt.cta._relativeUrls=true;hbspt.cta.load(3893111, '182e67c2-aa89-4b0b-b3e9-144293680ea4', {"useNewLoader":"true","region":"na1"});

Business Continuity Management Certified Planner-Specialist-Expert

hbspt.cta._relativeUrls=true;hbspt.cta.load(3893111, 'eb6856d2-cbb2-4a76-b237-7bd842e84226', {"useNewLoader":"true","region":"na1"});

hbspt.cta._relativeUrls=true;hbspt.cta.load(3893111, '182e67c2-aa89-4b0b-b3e9-144293680ea4', {"useNewLoader":"true","region":"na1"});

CBF-2 Pharmaceutical Procurement and Supply Management

More Information About Business Continuity Management Courses

Your Comments Here:

More Posts